

VPI/99-01 CON USIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Salituro *et al.* Art Unit: 1624  
Serial Number: 10/035,823 Examiner: McKenzie, T.  
Filing Date: October 23, 2001  
For: *Inhibitors of C-Jun N-Terminal Kinases*

COMMISSIONER FOR PATENTS  
WASHINGTON D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Examiner McKenzie:

In response to the Restriction Requirement mailed March 13, 2003, Applicants elect without traverse **Group I**, directed to claim 3 and parts of claims 1, 2, and 4-13, drawn to 3-oximino indoles, compounds of formula I with  $A^1-A^4$  = carbon and W= nitrogen, classified in class 548, subclass 438, among others.

A response to the Restriction Requirement was due April 13, 2003. However, since April 13, 2003 falls on a Sunday, Applicants respectfully submit that the filing of this response on Monday, April 14, 2003, the next business day after April 13, 2003, is timely. If it is believed that a telephone call would expedite prosecution, the Examiner is invited to contact the undersigned at (617) 444-6536. It is believed that there are no fees associated with this amendment; however, if Applicants are mistaken, the Commissioner is authorized to charge any fees (or credit any overpayments) to Deposit Account Number: 50-0725, reference number VPI/99-01 CON US.

Respectfully submitted,

Dated: APRIL 14, 2003



Karoline K. M. Shair, Ph.D.  
Registration No: 44,332  
Attorney for Applicants  
VERTEX PHARMACEUTICALS INC.  
130 Waverly Street  
Cambridge, Massachusetts 02139-4646  
Tel: (617) 444-6536  
Fax: (617) 444-6483